Location History:
- Mohlin, CH (2002 - 2004)
- Rheinfelden, CH (2016)
Company Filing History:
Years Active: 2002-2016
Title: The Innovations of Inventor Michael Ambuhl
Introduction
Michael Ambuhl, a notable inventor based in Mohlin, Switzerland, has contributed significantly to the field of pharmaceutical sciences. With three patents to his name, he has showcased his dedication to creating innovative solutions that enhance healthcare and medicine. Ambuhl currently works at Novartis AG, a global healthcare company renowned for its commitment to research and development.
Latest Patents
Among his latest patents, Michael Ambuhl has developed a notable process for making compositions comprising sphingosine 1 phosphate (S1P) receptor modulators. This invention pertains to stable compositions that include S1P receptor modulators, designed for use as dosage forms. The S1P receptor modulators often consist of sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or derivatives of 2-amino-propanol, which include compounds featuring a specific group of formula Y. Additionally, he has patented a pharmaceutical composition that consists of a cyclosporin and a carrier medium, further highlighting his expertise in creating effective medicinal formulations.
Career Highlights
Michael's career has been marked by a steadfast commitment to innovation in the pharmaceutical industry. His work at Novartis AG places him at the forefront of drug development, allowing him to leverage his inventive prowess to address pressing health challenges. His contributions have not only advanced the existing body of knowledge but have also opened new avenues for therapeutic strategies.
Collaborations
Throughout his career, Michael has collaborated with talented peers such as Barbara Lückel and Barbara Haberlin, fostering a community of innovation at Novartis AG. These collaborations have undoubtedly enriched his research and contributed to the success of his inventions.
Conclusion
Michael Ambuhl stands out as a remarkable inventor in the pharmaceutical arena. His innovative patents and collaborative efforts make a significant impact on medical science, providing essential advancements that benefit patients and healthcare professionals alike. As he continues his journey with Novartis AG, the potential for future breakthroughs remains promising.